Incidence of Acute Urine Retention: Randomized Clinical Trial Comparing Early, Mid or Late Urinary Catheter Removal in Patients With Rectal Resection
NCT ID: NCT04751149
Last Updated: 2021-02-11
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
143 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-05-01
Study Completion Date
2022-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
DESIGN:
Randomized, open-label and parallel clinical trial, assigned to early, mid, or late withdrawal of urinary catheter with a 1: 1: 1 allocation ratio.
POPULATION:
Patients undergoing anterior rectal resection, low rectal resection, or abdominoperineal amputation for any reason.
OBJECTIVES:
The main objective is to compare the incidence of acute urine retention after removal of the urinary catheter in the postoperative period of rectal resection.
Secondary objectives are:
1. Incidence of urinary tract infection after urinary catheter removal.
2. Incidence of specific postoperative complications (Surgical wound infection, Respiratory infection, Anastomotic dehiscence, ileus).
3. Incidence of postoperative complications assessed according to the Comprehensive Complication Index (CCI) scale.
DESCRIPTION OF THE INTERVENTION:
In all patients, a Rectal Resection (anterior rectal resection, posterior pelvic exenteration or abdominoperineal amputation) will be performed. In group 1A, the urinary catheter will be removed on the 1st postoperative day. In group 1B patients, the urinary catheter will be removed on the 3rd postoperative day. In group 1C patients, the urinary catheter will be removed on the 5th postoperative day. All patients will have a urine culture taken at the time of withdrawal.
Randomized, open-label and parallel clinical trial, assigned to early, mid, or late withdrawal of urinary catheter with a 1: 1: 1 allocation ratio.
POPULATION:
Patients undergoing anterior rectal resection, low rectal resection, or abdominoperineal amputation for any reason.
OBJECTIVES:
The main objective is to compare the incidence of acute urine retention after removal of the urinary catheter in the postoperative period of rectal resection.
Secondary objectives are:
1. Incidence of urinary tract infection after urinary catheter removal.
2. Incidence of specific postoperative complications (Surgical wound infection, Respiratory infection, Anastomotic dehiscence, ileus).
3. Incidence of postoperative complications assessed according to the Comprehensive Complication Index (CCI) scale.
DESCRIPTION OF THE INTERVENTION:
In all patients, a Rectal Resection (anterior rectal resection, posterior pelvic exenteration or abdominoperineal amputation) will be performed. In group 1A, the urinary catheter will be removed on the 1st postoperative day. In group 1B patients, the urinary catheter will be removed on the 3rd postoperative day. In group 1C patients, the urinary catheter will be removed on the 5th postoperative day. All patients will have a urine culture taken at the time of withdrawal.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immediate Versus Early (24-hours) Urinary Catheter Removal After Elective Minimally Invasive Colonic Resection
NCT05249192
Surgical Complication
Colonic Disease
Postoperative Complications
+2 more
COMPLETED
NA
Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.
NCT04612569
Rectal Cancer
Low Anterior Resection Syndrome
Faecal Incontinence
UNKNOWN
Removal Time of Urinary Catheter After Laparoscopic Anterior Resection of the Rectum
NCT03065855
Rectum Cancer
UNKNOWN
NA
Effect of Individualized Catheter Management on Early Removal After Rectal Cancer Surgery
NCT07346586
Urinary Catheters
Rectal Cancer
Urinary Retention
NOT_YET_RECRUITING
NA
Patient Reported Outcomes Following Cancer of the Rectum
NCT04936581
Sphincter Ani Incontinence
Rectal Cancer
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Currently there is a trend towards prolonged urinary catheterization in patients undergoing rectal resection surgery. However, there are studies that defend although there is a slight increase in AUR in these patients, it can be withdrawn early in a safe way with a lower incidence of UTI.
The aim of the study is to analyse whether there are differences in the incidence of AUR in rectal surgery patients and to observe whether it has an impact on other postoperative complications. A randomized clinical trial is proposed to compare an early, mid or late removal of the urinary catheter in patients with rectal resection.
\- Potential Risks and Benefits:
Both techniques, both early and late withdrawal, are approved practices that are carried out in a standardized way in the current practice. There are no potential risks associated with the study intervention, beyond the intrinsic risks of the procedure itself.
\- Objectives of the study:
Main objective: to compare the incidence of acute urine retention after removal of the urinary catheter in the postoperative period of rectal resection.
Secondary objectives:
Incidence of urinary tract infection after urinary catheter removal. Incidence of specific postoperative complications (surgical wound infection, respiratory infection, anastomotic dehiscence, ileus).
Incidence of postoperative complications assessed according to the Comprehensive Complication Index (CCI) scale.
* Variables:
* Demographic: sex, date of birth, BMI, ASA, Benign Prostate Hyperplasia, surgical history, usual treatment, date of diagnosis of the tumor, neoadjuvant treatment, tumor stage (TNM).
* Preoperative evaluation: IPSS (International Prostate Syndrome Score) for evaluation of preoperative urinary function in men.
* Surgical treatment: date of surgery, antibiotic prophylaxis, type of surgical approach, blood volume administered during surgery, mechanical preparation of the colon, type of surgery, ligation of the inferior mesenteric artery (IMA), need for intraoperative transfusion, duration of intervention, bleeding, intraoperative complications.
* Postoperative evolution: Acute retention of urine, urinary tract infection, surgical wound infection, respiratory infection, paralytic ileus, blood volume administered postoperatively, postoperative complications (ICC), date of diagnosis, reoperation, hospital stay, postoperative mortality and readmission .
* Evolution and follow-up: Need for catheterization, removal of urinary catheter, urinary tract infection.
* Definitions:
* Postoperative morbidity includes all postoperative complications that occurred during the first 30 postoperative days. Complications will be evaluated according to the CCI (classification that considers the accumulation of complications based on the Clavien-Dindo scale).
* Severe prostate symptomatology is considered to be an IPSS score (established questionnaire for prostate symptoms) greater than 20.
* Urinary catheter placement is considered to be the placement of a catheter through the urethra, always performed under antiseptic conditions.
* AUR is considered the impossibility of urine output despite urinary desire and at least 30 minutes, or anuria of 8 hours after the removal of the UC with a retention of more than 250 mL.
* UTI is defined as a positive urine culture with\> 10 5 bacterial colonies / mL of urine.
* Respiratory infection is considered a positive sputum culture and / or a chest radiograph with parenchymal condensations.
* The wound infection is considered deep, superficial or parastomal according to the CDC (Center for Disease Control) criteria for wound infections.
* A delay in oral tolerance due to vomiting, abdominal distention or the need for nasogastric tube placement will be considered ileus.
* Anastomotic dehiscence and its severity is defined according to the International Study Group of Rectal Cancer.
* Postoperative mortality is defined as death within the first 90 days after surgery or before hospital discharge.
* Readmission is defined as admission to the hospital within 30 days of discharge from the hospital.
* Neoadjuvant chemotherapy is considered to be that received prior to surgery.
* The duration of the surgical intervention is considered the time from the beginning of the skin section to the end of the last skin point, calculated in minutes.
* The volume administered during the surgery is considered the volume of fluids administered by the venous route from the induction of anesthesia to the extubation of the patient.
* A high ligation of the IMA is considered to be the ligation that is performed about 2 cm from the root of the IMA, preserving the superior hypogastric plexus. Low ligation of the IMA is considered one that is distal to the bifurcation of the IMA.
* Study Design:
* Randomized clinical trial, with an allocation ratio of 1: 1: 1, controlled, of patients undergoing rectal resection surgery.
* The study population is hospitalized patients, who underwent anterior rectal resection, low anterior rectal resection or abdominoperineal amputation of any etiology.
* It is a single-center trial.
* The expected recruitment period is 36 months. The follow-up time of the patients in the study is 30 days.
* The approximate duration of the study is 3 years.
Calculation of the sample size:
According to published clinical trials, up to 30% of rectal surgery patients who have VS removed will have an AUR for the first POD. The estimated risk of AUR after removal of VS on the 3rd PDO is 5%. If a confidence level at 95% is set and a statistical power of 80% is desired and having an expected proportion of losses of 10% in each group, the sample size should be 48 in each group.
Randomization process:
Patients who meet the inclusion criteria for the study will be randomized using random number generator functions with the SPSS v.25 program in the UC withdrawal group on the first, third and fifth postoperative days. The randomization will be 1: 1: 1.
Allocation concealment will be done by sealed opaque envelopes. The envelope will be opened inside the operating room at the beginning of the surgical procedure.
Masking process:
Patients, surgeons, and research staff know the intervention group to which the patient have been assigned.
Dropouts, withdrawals and losses
* Dropouts: patients included in a clinical trial who are unwilling or unable to continue in the study or in follow-up.
* Withdrawals: patients who are forced to abandon the study due to the appearance of exclusion criteria, but whose follow-up is feasible.
* Loss of follow-up: patients included in the study, who do not carry out the indicated controls, for whom it is not possible to obtain follow-up data.
* Criteria for Inclusion and Exclusion
• INCLUSION CRITERIA:
* Patients undergoing programmed rectal surgery.
* Age ≥ 18 years and \<85 years.
* Any type of tumor, any T, N, M.
* Consent signed by the patient and the researcher.
• EXCLUSION CRITERIA:
* IPSS\> 20
* Transanal resection.
* Urinary catheterization in the 7 days prior to surgery.
* Patients taking treatment for benign prostatic hyperplasia.
* Urine infection in the month prior to surgery.
* Patients with chronic kidney failure with Creatinine\> 2 mg / dL.
* Enterovesical fistula.
* Neurogenic bladder.
* Patients with a sacral nerve stimulator or artificial sphincter.
* Inability to read or understand any of the languages of informed consent.
* Emergency surgery.
* Psychiatric illnesses, addictions or any disorder that prevents the understanding of informed consent.
* Description of the intervention:
Management common to all patients included in the study:
Lithotomy position for surgery, regardless of whether it is subsequently modified to the prone position. Laparotomy or laparoscopic surgery, performing Anterior Rectum Resection, Lower Anterior Resection, with or without anastomosis or Abdominoperineal Resection.
Transurethral 16 Fr Foley catheter placement. Balanced general anesthesia, with or without epidural catheter, at the discretion of the responsible anesthesiologist. Avoid hydric overload and favor normothermia.
Positioning of the usual trocars (but modifiable according to the surgeon's preferences). An oncological or transmesorectal mesorectal dissection will be performed according to the needs of each patient, always trying to identify the upper and lower hypogastric plexus, without injuring them. The inferior mesenteric artery will be cut at least 2 cm from the root to avoid the superior hypogastric plexus or a distal ligation with preservation of the left colic artery. The extraction of the sample will be by a Minipfannenstiel, laparotomy or perineum.
In group 1A, the UC will be removed in the first 24 hours after surgery, accompanied by a urine culture taken from UC. In group 1B, the UC will be removed approximately 72 hours after surgery, accompanied by a urine culture taken for UC. In group 1C, the UC will be removed approximately 96 hours after surgery, accompanied by a urine culture taken from UC.
In cases of APR, the UC will be replaced, which will be maintained for at least 4 more days, at which point its removal will be attempted again along with taking another urine culture.
Complications data will be collected together with the other variables in the data collection sheet.
The other fast-track principles approved by different participating centers will be applied.
The aim of the study is to analyse whether there are differences in the incidence of AUR in rectal surgery patients and to observe whether it has an impact on other postoperative complications. A randomized clinical trial is proposed to compare an early, mid or late removal of the urinary catheter in patients with rectal resection.
\- Potential Risks and Benefits:
Both techniques, both early and late withdrawal, are approved practices that are carried out in a standardized way in the current practice. There are no potential risks associated with the study intervention, beyond the intrinsic risks of the procedure itself.
\- Objectives of the study:
Main objective: to compare the incidence of acute urine retention after removal of the urinary catheter in the postoperative period of rectal resection.
Secondary objectives:
Incidence of urinary tract infection after urinary catheter removal. Incidence of specific postoperative complications (surgical wound infection, respiratory infection, anastomotic dehiscence, ileus).
Incidence of postoperative complications assessed according to the Comprehensive Complication Index (CCI) scale.
* Variables:
* Demographic: sex, date of birth, BMI, ASA, Benign Prostate Hyperplasia, surgical history, usual treatment, date of diagnosis of the tumor, neoadjuvant treatment, tumor stage (TNM).
* Preoperative evaluation: IPSS (International Prostate Syndrome Score) for evaluation of preoperative urinary function in men.
* Surgical treatment: date of surgery, antibiotic prophylaxis, type of surgical approach, blood volume administered during surgery, mechanical preparation of the colon, type of surgery, ligation of the inferior mesenteric artery (IMA), need for intraoperative transfusion, duration of intervention, bleeding, intraoperative complications.
* Postoperative evolution: Acute retention of urine, urinary tract infection, surgical wound infection, respiratory infection, paralytic ileus, blood volume administered postoperatively, postoperative complications (ICC), date of diagnosis, reoperation, hospital stay, postoperative mortality and readmission .
* Evolution and follow-up: Need for catheterization, removal of urinary catheter, urinary tract infection.
* Definitions:
* Postoperative morbidity includes all postoperative complications that occurred during the first 30 postoperative days. Complications will be evaluated according to the CCI (classification that considers the accumulation of complications based on the Clavien-Dindo scale).
* Severe prostate symptomatology is considered to be an IPSS score (established questionnaire for prostate symptoms) greater than 20.
* Urinary catheter placement is considered to be the placement of a catheter through the urethra, always performed under antiseptic conditions.
* AUR is considered the impossibility of urine output despite urinary desire and at least 30 minutes, or anuria of 8 hours after the removal of the UC with a retention of more than 250 mL.
* UTI is defined as a positive urine culture with\> 10 5 bacterial colonies / mL of urine.
* Respiratory infection is considered a positive sputum culture and / or a chest radiograph with parenchymal condensations.
* The wound infection is considered deep, superficial or parastomal according to the CDC (Center for Disease Control) criteria for wound infections.
* A delay in oral tolerance due to vomiting, abdominal distention or the need for nasogastric tube placement will be considered ileus.
* Anastomotic dehiscence and its severity is defined according to the International Study Group of Rectal Cancer.
* Postoperative mortality is defined as death within the first 90 days after surgery or before hospital discharge.
* Readmission is defined as admission to the hospital within 30 days of discharge from the hospital.
* Neoadjuvant chemotherapy is considered to be that received prior to surgery.
* The duration of the surgical intervention is considered the time from the beginning of the skin section to the end of the last skin point, calculated in minutes.
* The volume administered during the surgery is considered the volume of fluids administered by the venous route from the induction of anesthesia to the extubation of the patient.
* A high ligation of the IMA is considered to be the ligation that is performed about 2 cm from the root of the IMA, preserving the superior hypogastric plexus. Low ligation of the IMA is considered one that is distal to the bifurcation of the IMA.
* Study Design:
* Randomized clinical trial, with an allocation ratio of 1: 1: 1, controlled, of patients undergoing rectal resection surgery.
* The study population is hospitalized patients, who underwent anterior rectal resection, low anterior rectal resection or abdominoperineal amputation of any etiology.
* It is a single-center trial.
* The expected recruitment period is 36 months. The follow-up time of the patients in the study is 30 days.
* The approximate duration of the study is 3 years.
Calculation of the sample size:
According to published clinical trials, up to 30% of rectal surgery patients who have VS removed will have an AUR for the first POD. The estimated risk of AUR after removal of VS on the 3rd PDO is 5%. If a confidence level at 95% is set and a statistical power of 80% is desired and having an expected proportion of losses of 10% in each group, the sample size should be 48 in each group.
Randomization process:
Patients who meet the inclusion criteria for the study will be randomized using random number generator functions with the SPSS v.25 program in the UC withdrawal group on the first, third and fifth postoperative days. The randomization will be 1: 1: 1.
Allocation concealment will be done by sealed opaque envelopes. The envelope will be opened inside the operating room at the beginning of the surgical procedure.
Masking process:
Patients, surgeons, and research staff know the intervention group to which the patient have been assigned.
Dropouts, withdrawals and losses
* Dropouts: patients included in a clinical trial who are unwilling or unable to continue in the study or in follow-up.
* Withdrawals: patients who are forced to abandon the study due to the appearance of exclusion criteria, but whose follow-up is feasible.
* Loss of follow-up: patients included in the study, who do not carry out the indicated controls, for whom it is not possible to obtain follow-up data.
* Criteria for Inclusion and Exclusion
• INCLUSION CRITERIA:
* Patients undergoing programmed rectal surgery.
* Age ≥ 18 years and \<85 years.
* Any type of tumor, any T, N, M.
* Consent signed by the patient and the researcher.
• EXCLUSION CRITERIA:
* IPSS\> 20
* Transanal resection.
* Urinary catheterization in the 7 days prior to surgery.
* Patients taking treatment for benign prostatic hyperplasia.
* Urine infection in the month prior to surgery.
* Patients with chronic kidney failure with Creatinine\> 2 mg / dL.
* Enterovesical fistula.
* Neurogenic bladder.
* Patients with a sacral nerve stimulator or artificial sphincter.
* Inability to read or understand any of the languages of informed consent.
* Emergency surgery.
* Psychiatric illnesses, addictions or any disorder that prevents the understanding of informed consent.
* Description of the intervention:
Management common to all patients included in the study:
Lithotomy position for surgery, regardless of whether it is subsequently modified to the prone position. Laparotomy or laparoscopic surgery, performing Anterior Rectum Resection, Lower Anterior Resection, with or without anastomosis or Abdominoperineal Resection.
Transurethral 16 Fr Foley catheter placement. Balanced general anesthesia, with or without epidural catheter, at the discretion of the responsible anesthesiologist. Avoid hydric overload and favor normothermia.
Positioning of the usual trocars (but modifiable according to the surgeon's preferences). An oncological or transmesorectal mesorectal dissection will be performed according to the needs of each patient, always trying to identify the upper and lower hypogastric plexus, without injuring them. The inferior mesenteric artery will be cut at least 2 cm from the root to avoid the superior hypogastric plexus or a distal ligation with preservation of the left colic artery. The extraction of the sample will be by a Minipfannenstiel, laparotomy or perineum.
In group 1A, the UC will be removed in the first 24 hours after surgery, accompanied by a urine culture taken from UC. In group 1B, the UC will be removed approximately 72 hours after surgery, accompanied by a urine culture taken for UC. In group 1C, the UC will be removed approximately 96 hours after surgery, accompanied by a urine culture taken from UC.
In cases of APR, the UC will be replaced, which will be maintained for at least 4 more days, at which point its removal will be attempted again along with taking another urine culture.
Complications data will be collected together with the other variables in the data collection sheet.
The other fast-track principles approved by different participating centers will be applied.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Rectal Cancer
Retention, Urinary
Urinary Tract Infections
Surgical Site Infection
Anastomotic Leak
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Early removal of urinary catheter Medial removal of urinary catheter Late removal of urinary catheter
Primary Study Purpose
PREVENTION
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early Urinary Catheter Removal
Urinary Catheter will be removed the first postoperative day after rectal resection
Group Type
EXPERIMENTAL
Removal of Urinary Catheter
Intervention Type
PROCEDURE
Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
Medium Urinary Catheter Removal
Urinary Catheter will be removed the third postoperative day after rectal resection
Group Type
EXPERIMENTAL
Removal of Urinary Catheter
Intervention Type
PROCEDURE
Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
Late Urinary Catheter Removal
Urinary Catheter will be removed the fifth postoperative day after rectal resection
Group Type
EXPERIMENTAL
Removal of Urinary Catheter
Intervention Type
PROCEDURE
Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Removal of Urinary Catheter
Urinary catheter will be removed in aeseptic conditions. Before the removal a urinary culture will be obtained from the catheter.
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing programmed rectal surgery.
* Age ≥ 18 years and \<85 years.
* Any type of tumor, any T, N, M.
* Consent signed by the patient and the researcher.
* Age ≥ 18 years and \<85 years.
* Any type of tumor, any T, N, M.
* Consent signed by the patient and the researcher.
Exclusion Criteria
* IPSS\> 20
* Transanal local resection.
* Urinary catheterization in the 7 days prior to surgery.
* Patients taking treatment for benign prostatic hyperplasia.
* Urine infection in the month prior to surgery.
* Patients with chronic kidney failure with Creatinine\> 2 mg / dL.
* Enterovesical fistula.
* Neurogenic bladder.
* Patients with a sacral nerve stimulator or artificial sphincter.
* Inability to read or understand any of the languages of informed consent.
* Emergency surgery.
* Psychiatric illnesses, addictions or any disorder that prevents the understanding of informed consent.
* Transanal local resection.
* Urinary catheterization in the 7 days prior to surgery.
* Patients taking treatment for benign prostatic hyperplasia.
* Urine infection in the month prior to surgery.
* Patients with chronic kidney failure with Creatinine\> 2 mg / dL.
* Enterovesical fistula.
* Neurogenic bladder.
* Patients with a sacral nerve stimulator or artificial sphincter.
* Inability to read or understand any of the languages of informed consent.
* Emergency surgery.
* Psychiatric illnesses, addictions or any disorder that prevents the understanding of informed consent.
Minimum Eligible Age
18 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Donostia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Jose M Enríquez-Navascués
PhD; Head of service
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Maria Enriquez-Navascues, PhD
Role: PRINCIPAL_INVESTIGATOR
H Donostia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Donostia
Donostia / San Sebastian, Guipuzcos, Spain
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Spain
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Barone JG, Cummings KB. Etiology of acute urinary retention following benign anorectal surgery. Am Surg. 1994 Mar;60(3):210-1.
Reference Type
BACKGROUND
Sartori CA, Sartori A, Vigna S, Occhipinti R, Baiocchi GL. Urinary and sexual disorders after laparoscopic TME for rectal cancer in males. J Gastrointest Surg. 2011 Apr;15(4):637-43. doi: 10.1007/s11605-011-1459-0. Epub 2011 Feb 17.
Reference Type
BACKGROUND
Keating JP. Sexual function after rectal excision. ANZ J Surg. 2004 Apr;74(4):248-59. doi: 10.1111/j.1445-2197.2004.02954.x.
Reference Type
BACKGROUND
George D, Pramil K, Kamalesh NP, Ponnambatheyil S, Kurumboor P. Sexual and urinary dysfunction following laparoscopic total mesorectal excision in male patients: A prospective study. J Minim Access Surg. 2018 Apr-Jun;14(2):111-117. doi: 10.4103/jmas.JMAS_93_17.
Reference Type
BACKGROUND
Zmora O, Madbouly K, Tulchinsky H, Hussein A, Khaikin M. Urinary bladder catheter drainage following pelvic surgery--is it necessary for that long? Dis Colon Rectum. 2010 Mar;53(3):321-6. doi: 10.1007/DCR.06013e3181c7525c.
Reference Type
BACKGROUND
Patel DN, Felder SI, Luu M, Daskivich TJ, N Zaghiyan K, Fleshner P. Early Urinary Catheter Removal Following Pelvic Colorectal Surgery: A Prospective, Randomized, Noninferiority Trial. Dis Colon Rectum. 2018 Oct;61(10):1180-1186. doi: 10.1097/DCR.0000000000001206.
Reference Type
BACKGROUND
Petros JG, Bradley TM. Factors influencing postoperative urinary retention in patients undergoing surgery for benign anorectal disease. Am J Surg. 1990 Apr;159(4):374-6. doi: 10.1016/s0002-9610(05)81274-7.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ELO-RAO-2019-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Early and Late Removal of the Urinary Catheter After Rectum Resection
NCT05020613
UNKNOWN
NA
Organ/Space Surgical Site Infection and Recurrence and Survival in Rectal Cancer Surgery
NCT06382415
COMPLETED
Abdominoperineal Extra-Elevators Rectal Resection for Cancer: Prone Position vs. Supine Position
NCT02163785
TERMINATED
NA
Timing Evaluation of Stoma Closure (TIMES). Early vs Late Closure of Stoma After Rectal Cancer Surgery.
NCT05284864
UNKNOWN
NA
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
NCT03283540
ACTIVE_NOT_RECRUITING
Urinary Retention Following taTME VS laTME Total Mesorectal Excision for Rectal Cancer
NCT06147492
COMPLETED
NA
Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection for Rectum Cancer
NCT01062334
UNKNOWN
NA
Selection of Surgical Technique in Rectal Cancer
NCT06442215
RECRUITING
Robotic vs. TaTME Rectal Surgery (ROTA STUDY)
NCT04200027
NOT_YET_RECRUITING
Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior Resection
NCT02746224
COMPLETED
NA
Effectiveness of Pelvic Floor Exercise to Prevent LARS (Low Anterior Resection Syndrome)
NCT06519006
RECRUITING
NA
Peritoneal Microdialysis in Patients Undergoing Low Anterior Resection (LAR) for Recto-sigmoid Cancer
NCT00271986
COMPLETED
Prospective Randomised Study Comparing Laparoscopic Versus Open Surgery in Patients With Rectal Cancer
NCT00782457
COMPLETED
PHASE3
Treatment of "Low Anterior Resection Syndrome" by Percutaneous Nerve Evaluation and Transanal Irrigation
NCT01313026
TERMINATED
NA
Randomized Prospective Trial for Laparoscopic vs Open Resection for Rectal Cancer
NCT00470951
UNKNOWN
PHASE3
Duration of Urinary Catheterization
NCT04359069
RECRUITING
NA
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
NCT03520088
UNKNOWN
NA
Perioperative and Postoperative Evaluation of Rectal and Urogenital Function in Patients Undergoing Rectal Resection
NCT05257746
RECRUITING
Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow
NCT02401100
COMPLETED
The Impact of Transanal Decompression Tube Placement After Colorectal Anastomosis: A Randomized Trial
NCT04890015
UNKNOWN
NA
Evaluation of Short-term Outcomes of Day Surgery for Patients With CuRC
NCT04646915
UNKNOWN
Prospective, Controlled, Randomized Multicentric Study on the Management of the Vesical Catheter in Colon Surgery.
NCT04070898
UNKNOWN
NA
Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol in Gastric Surgery for Cancer
NCT03865810
UNKNOWN
Prehabilitation in Geriatric Patients With Colorectal Neoplasia
NCT05851235
UNKNOWN
NA